Long acting GLP-1 receptor agonist (injectable)
Efpeglenatide 8 mg injection every 4 weeks
EFPE_SC_8MG_Q4W
Related
- All doses pooled: Efpe sc
- Efpe sc 1mg qw
- Efpeglenatide 2 mg subcutaneous once weekly
- Efpeglenatide 4 mg subcutaneous once weekly
- Efpe sc 8mg qm
- Efpe sc 12mg qm
- Efpeglenatide 16 mg injection monthly
- Efpeglenatide 12 mg injection every 4 weeks
- Efpeglenatide 16 mg injection every 4 weeks
- Efpeglenatide 6 mg subcutaneous once weekly
- Efpeglenatide 6 mg injection every 2 weeks
- Efpeglenatide 8 mg injection every 2 weeks
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.60 (0.01 to 42.08) | 0.67 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.11 (0.00 to 1.44) | 0.88 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 3.63 (0.79 to 20.26) | 0.28 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 7.55 (2.07 to 35.26) | 0.18 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.01 (0.81 to 12.72) | 0.46 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.09 (0.69 to 7.22) | 0.39 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.85 (0.05 to 13.15) | 0.47 |